Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 27, 1999
Grant Date -
N/A
app pub date -
Jun 23, 1997
filing date -
Jun 23, 1997
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully